首页 › 基金 › Elmind Capital, LP › CLDX
Elmind Capital, LP 对 CLDX 的持仓历史
CELLDEX THERAPEUTICS INC NEW · 医疗保健
Elmind Capital, LP 在 Q2 2026 的 13F 申报中披露持有 CLDX(CELLDEX THERAPEUTICS INC NEW)990,000 股,市值约 US$36.8M,约占其申报组合的 9.25%,在其申报持仓中市值排名第 3 位。 Elmind Capital, LP 最近 3 个申报季度中有 3 个季度披露了 CLDX 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
Elmind Capital, LP 对 CLDX 的持仓演变
Elmind Capital, LP 于 Q4 2025 首次披露 CLDX 持仓:865,000 股(约 US$23.5M)。 该持仓在 Q2 2026 达到峰值 990,000 股,市值约 US$36.8M。 在 3 次申报中,Elmind Capital, LP 1 次增持、0 次减持、1 次保持不变。 最近一期申报(Q2 2026)显示持股 990,000 股、市值约 US$36.8M,环比增持 125,000 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 865.00K | $23.49M | 新进 |
| Q1 2026 | 865.00K | $27.44M | 持有 |
| Q2 2026 | 990.00K | $36.84M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 CLDX 与 13F 数据
CLDX(CELLDEX THERAPEUTICS INC NEW)属于医疗保健行业。我们追踪的基金中还有 43 只申报持有 CLDX,申报仓位最大的包括:Kynam Capital Management, LP (US$198.1M), Deep Track Capital, LP (US$109.4M), Logos Global Management LP (US$78.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 CLDX 的基金
- Kynam Capital Management, LP 5.32M 股 · $198.07M · Q2 2026
- Deep Track Capital, LP 2.94M 股 · $109.37M · Q2 2026
- Logos Global Management LP 2.10M 股 · $78.14M · Q2 2026
- Eversept Partners, LP 1.79M 股 · $66.45M · Q2 2026
- Commodore Capital LP 1.35M 股 · $50.23M · Q2 2026
- Bellevue Group AG 1.20M 股 · $44.65M · Q2 2026
- BAKER BROS. ADVISORS LP 1.18M 股 · $44.00M · Q2 2026
- Novo Holdings A/S 1.02M 股 · $38.14M · Q2 2026
- Foresite Capital Management VI LLC 879.71K 股 · $32.73M · Q2 2026
- Affinity Asset Advisors, LLC 700.00K 股 · $26.05M · Q2 2026
- Rock Springs Capital Management LP 699.15K 股 · $26.02M · Q2 2026
- ADAR1 Capital Management, LLC 619.54K 股 · $23.05M · Q2 2026
更多关于 Elmind Capital, LP
常见问题
How long has Elmind Capital, LP held CLDX?
Elmind Capital, LP has disclosed CLDX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Elmind Capital, LP's current position in CLDX?
As of Q2 2026, Elmind Capital, LP holds 990.00K shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $36.84M, representing 9.25% of its reported portfolio and ranking #3.
Has Elmind Capital, LP been buying or selling CLDX?
In the latest 13F filing (Q2 2026), Elmind Capital, LP increased its position in CLDX. The position peaked in Q2 2026 at 990.00K shares.
Which other funds hold CLDX?
Other major institutional holders of CLDX include Kynam Capital Management, LP, Deep Track Capital, LP, Logos Global Management LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.